- Messages
- 8,453
- Type of diabetes
- Type 2
- Treatment type
- Tablets (oral)
I have on several occasions asked forum posters who are using this family of diabetes medication if their prescriber has discussed the symptoms of DKA with them in regard to this family of medications. So far none has replied that this happened, so I am starting this thread with the current Government advisory from both the UK and USA. I cannot find any NICE guidelines to GP's covering this aspect but there was an internal assessment report I found that discusses this topic. The report is not for public release. It discusses the reported incidence rates for DKA and acute pancreatis but has no recommendations other than wait for more FDA investigation studies to complete.
The following advisories are released and updated by the regulatory authorities:
https://www.gov.uk/drug-safety-upda...d-advice-on-the-risk-of-diabetic-ketoacidosis
http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm
I really think this should be made into a sticky so it does not get lost. DKA is a potentially life threatening condition that can apparently be triggered by these meds even on lowish bgl levels (10 mmol/l) so is not the same as the classic DKA symptoms where there is very high bgl with it.
@Giverny
The report that the NICE comittee used to base their decision on is available on the web
https://www.nice.org.uk/guidance/ta336/chapter/4-Consideration-of-the-evidence
It is interesting that the Company ran all the tests and presented the findings. The tests were short duration and the only side effect noted in the summary was UTI. The incidence of bone thickening and fracture was not reported, and DKA was not considered. There was no seperate chapter on SAFETY at all, and long term safety did not seem to be a consideration.
The current guidelines for prescription do not mention either of these 'side effects either.
https://www.nice.org.uk/guidance/ta390/chapter/3-Evidence
Edit to add a couple of related topics:
Sglt2 Inhibitors Continue To Be Linked With Amputation Risk In Type 2 Diabetes
https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2696726
And another related study on mortality associated with this medication:
https://jamanetwork.com/journals/ja...t=personalizedcontent&previousarticle=2696726
The following advisories are released and updated by the regulatory authorities:
https://www.gov.uk/drug-safety-upda...d-advice-on-the-risk-of-diabetic-ketoacidosis
http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm
I really think this should be made into a sticky so it does not get lost. DKA is a potentially life threatening condition that can apparently be triggered by these meds even on lowish bgl levels (10 mmol/l) so is not the same as the classic DKA symptoms where there is very high bgl with it.
@Giverny
The report that the NICE comittee used to base their decision on is available on the web
https://www.nice.org.uk/guidance/ta336/chapter/4-Consideration-of-the-evidence
It is interesting that the Company ran all the tests and presented the findings. The tests were short duration and the only side effect noted in the summary was UTI. The incidence of bone thickening and fracture was not reported, and DKA was not considered. There was no seperate chapter on SAFETY at all, and long term safety did not seem to be a consideration.
The current guidelines for prescription do not mention either of these 'side effects either.
https://www.nice.org.uk/guidance/ta390/chapter/3-Evidence
Edit to add a couple of related topics:
Sglt2 Inhibitors Continue To Be Linked With Amputation Risk In Type 2 Diabetes
https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2696726
And another related study on mortality associated with this medication:
https://jamanetwork.com/journals/ja...t=personalizedcontent&previousarticle=2696726
Last edited: